Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE000000735
CNY
29.07
0.37 (1.29%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationAnnual Results
Results Snapshot
Figures in Million
Consolidate Annual Results
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
Dec'19
Dec'18
Net Sales
1,312.66
1,462.67
1,459.18
1,504.03
1,102.05
1,956.21
2,070.59
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
1,312.66
1,462.67
1,459.18
1,504.03
1,102.05
1,956.21
2,070.59
Raw Material Cost
364.54
410.35
384.22
381.47
252.51
371.09
370.72
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
134.73
134.39
142.87
149.47
148.19
152.23
121.79
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
82.78
83.85
88.94
97.77
123.16
49.10
39.89
Selling and Distribution Expenses
759.06
881.73
893.83
951.02
1,148.64
1,475.07
1,377.84
Other Expenses
-16.99
-17.33
-16.79
-18.44
-22.16
-13.49
-9.50
Total Expenditure (Excl Depreciation)
1,171.19
1,337.01
1,341.99
1,395.35
1,450.93
1,912.55
1,815.28
Operating Profit (PBDIT) excl Other Income
141.5
125.7
117.2
108.69999999999999
-348.9
43.7
255.3
Other Income
12.07
17.48
20.30
42.36
145.29
70.99
198.07
Operating Profit (PBDIT)
214.96
216.14
209.72
229.77
-139.55
180.67
524.36
Interest
82.78
83.85
88.94
97.77
123.16
49.10
39.89
Exceptional Items
0.25
1.34
0.79
-0.99
-15.43
-2,071.32
-6.20
Gross Profit (PBDT)
948.11
1,052.32
1,074.95
1,122.56
849.53
1,585.12
1,699.87
Depreciation
67.38
75.03
71.80
70.00
69.70
69.95
69.02
Profit Before Tax
65.06
58.60
49.77
61.01
-347.83
-2,009.71
409.25
Tax
11.11
11.63
20.99
25.64
4.83
30.19
80.03
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
56.44
43.93
30.15
35.27
-359.50
-2,041.89
330.86
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
56.44
43.93
30.15
35.27
-359.50
-2,041.89
330.86
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
-0.46
-0.71
-0.96
-1.29
-1.16
-1.05
-1.64
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
55.98
43.23
29.19
33.99
-360.66
-2,042.94
329.22
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
2,255.40
2,317.66
2,336.86
2,306.71
2,271.43
2,630.93
4,672.82
Earnings per share (EPS)
0.06
0.05
0.03
0.04
-0.37
-2.11
0.34
Diluted Earnings per share
0.06
0.05
0.03
0.04
-0.37
-2.11
0.34
Operating Profit Margin (Excl OI)
10.32%
8.45%
8.06%
7.81%
-32.17%
2.03%
12.42%
Gross Profit Margin
10.09%
9.14%
8.33%
8.71%
-25.24%
-99.16%
23.1%
PAT Margin
4.3%
3.0%
2.07%
2.35%
-32.62%
-104.38%
15.98%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Annual Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Dec 2024 is -10.26% vs 0.24% in Dec 2023

stock-summary

Consolidate Net Profit

YoY Growth in year ended Dec 2024 is 29.63% vs 47.95% in Dec 2023

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Dec 2024 is 2.11% vs 4.91% in Dec 2023

stock-summary

Interest

YoY Growth in year ended Dec 2024 is -1.19% vs -5.74% in Dec 2023

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in year ended Dec 2024 has improved from Dec 2023

Compare Annual Results Of Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. With
Markets Mojo
Figures in Million
Consolidate Annual Results
Markets Mojo
Markets Mojo
Change(CNY)
Change(%)
Net Sales
1,312.66
0
1,312.66
Other Operating Income
0.00
0.00
0.00
Total Operating income
1,312.66
0
1,312.66
Raw Material Cost
364.54
0
364.54
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
134.73
0
134.73
Power Cost
0
0
0.00
Manufacturing Expenses
82.78
0
82.78
Selling and Distribution Expenses
759.06
0
759.06
Other Expenses
-16.99
0.00
-16.99
Total Expenditure (Excl Depreciation)
1,171.19
0
1,171.19
Operating Profit (PBDIT) excl Other Income
141.47
0.00
141.47
Other Income
12.07
0
12.07
Operating Profit (PBDIT)
214.96
0
214.96
Interest
82.78
0
82.78
Exceptional Items
0.25
0
0.25
Gross Profit (PBDT)
948.11
0
948.11
Depreciation
67.38
0
67.38
Profit Before Tax
65.06
0
65.06
Tax
11.11
0
11.11
Provisions and contingencies
0
0
0.00
Profit After Tax
56.44
0
56.44
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
56.44
0
56.44
Share in Profit of Associates
0
0
0.00
Minority Interest
-0.46
0
-0.46
Other related items
0.00
0.00
0.00
Consolidated Net Profit
55.98
0
55.98
Equity Capital
0
0
0.00
Face Value
1.00
0
0.00
Reserves
2,255.40
0
2,255.40
Earnings per share (EPS)
0.06
0
0.06
Diluted Earnings per share
0.06
0
0.06
Operating Profit Margin (Excl OI)
10.32%
0%
0.00
10.32%
Gross Profit Margin
10.09%
0%
0.00
10.09%
PAT Margin
4.30%
0%
0.00
4.30%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Annual - Net Sales
Net Sales 131.27 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is -10.26% vs 0.24% in Dec 2023

Annual - Consolidate Net Profit
Consolidate Net Profit 5.60 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 29.63% vs 47.95% in Dec 2023

Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 20.29 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 2.11% vs 4.91% in Dec 2023

Annual - Interest
Interest 8.28 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is -1.19% vs -5.74% in Dec 2023

Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 10.32%
in Dec 2024

Figures in %
stock-summary

YoY Growth in year ended Dec 2024 has improved from Dec 2023